# Sacrifice or preserve the superior petrosal vein in microvascular decompression surgery: a systematic review and meta-analysis

Shahab Aldin Sattari, MD,<sup>1</sup> Ataollah Shahbandi,<sup>2</sup> Risheng Xu, MD, PhD,<sup>1</sup> Alice Hung, MD,<sup>1</sup> James Feghali, MD,<sup>1</sup> Wuyang Yang, MD,<sup>1</sup> Ryan P. Lee, MD,<sup>1</sup> Chetan Bettegowda, MD, PhD,<sup>1</sup> and Judy Huang, MD<sup>1</sup>

<sup>1</sup>Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; and <sup>2</sup>Tehran School of Medicine, Tehran University of Medical Science, Tehran, Iran

**OBJECTIVE** In microvascular decompression (MVD) surgery through the retrosigmoid approach, the surgeon may have to sacrifice the superior petrosal vein (SPV). However, this is a controversial maneuver. To date, high-level evidence comparing the operative outcomes of patients who underwent MVD with and without SPV sacrifice is lacking. Therefore, this study sought to bridge this gap.

**METHODS** The authors searched the Medline and PubMed databases with appropriate Medical Subject Heading (MeSH) terms and keywords. The primary outcome was vascular-related complications; secondary outcomes were new neurological deficit, cerebrospinal fluid (CSF) leak, and neuralgia relief. The pooled proportions of outcomes and OR (95% CI) for categorical data were calculated by using the logit transformation and Mantel-Haenszel methods, respectively.

**RESULTS** Six studies yielding 1143 patients were included, of which 618 patients had their SPV sacrificed. The pooled proportion (95% CI) values were 3.82 (0.87-15.17) for vascular-related complications, 3.64 (1.0-12.42) for new neurological deficits, 2.85 (1.21-6.58) for CSF leaks, and 88.90 (84.90-91.94) for neuralgia relief. The meta-analysis concluded that, whether the surgeon sacrificed or preserved the SPV, the odds were similar for vascular-related complications (2.5% vs 1.5%, OR [95% CI] 1.01 [0.33-3.09], p = 0.99), new neurological deficits (1.2% vs 2.8%, OR [95% CI] 0.55 [0.18-1.66], p = 0.29), CSF leak (3.1% vs 2.1%, OR [95% CI] 1.16 [0.46-2.94], p = 0.75), and neuralgia relief (86.6% vs 87%, OR [95% CI] 0.96 [0.62-1.49], p = 0.84).

**CONCLUSIONS** SPV sacrifice is as safe as SPV preservation. The authors recommend intentional SPV sacrifice when gentle retraction fails to enhance surgical field visualization and if the surgeon encounters SPV-related neurovascular conflict and/or anticipates impeding SPV-related bleeding.

https://thejns.org/doi/abs/10.3171/2022.5.JNS22143

**KEYWORDS** Dandy's vein; superior petrosal vein; microvascular decompression; retrosigmoid approach; trigeminal neuralgia; meta-analysis; pain; surgical technique

M ICROVASCULAR decompression (MVD) has been known as the benchmark surgical procedure for the treatment of intractable trigeminal neuralgia (TN), hemifacial spasm, glossopharyngeal neuralgia, and other cranial nerve rhizopathies.<sup>1-7</sup> As initially described by Walter E. Dandy, the superior petrosal vein (SPV) is the most frequently encountered venous structure during posterior fossa surgery and serves as a prominent landmark in the retrosigmoid approach (Fig. 1).<sup>7-10</sup> The SPV drains infratentorial structures into the superior petrosal

sinus (SPS) in 3 distinct patterns. In type I (19% of patients), the SPV enters the SPS superolateral to the internal acoustic meatus (IAM); type II (72%), the SPV joins the SPS between IAM and Meckel's cave just lateral to the trigeminal trunk; and type III (9%), the SPV empties into the SPS superior or medial to Meckel's cave.<sup>11</sup> Therefore, in the majority of patients, the SPV crosses the retrosigmoid corridor lateral to the trigeminal nerve, thereby obscuring the surgeon's view.<sup>9,11,12</sup>

During the retrosigmoid approach for MVD surgery,

ABBREVIATIONS CSF = cerebrospinal fluid; IAM = internal acoustic meatus; MVD = microvascular decompression; PICO = patient, intervention, comparator, and outcome; SPS = superior petrosal sinus; SPV = superior petrosal vein; TN = trigeminal neuralgia. SUBMITTED January 19, 2022. ACCEPTED May 5, 2022.

INCLUDE WHEN CITING Published online July 1, 2022; DOI: 10.3171/2022.5.JNS22143.



**FIG. 1.** This illustrative image shows the anatomical relationships of Dandy's vein (SPV) in the retrosigmoid approach. AICA = anterior inferior cerebellar artery; CN = cranial nerve; SCA = superior cerebellar artery. Tim Phelps © 2022 JHU AAM Department of Art as Applied to Medicine, The Johns Hopkins University School of Medicine.

surgeons may have to sacrifice the SPV.<sup>1,2,8,13</sup> However, this is a controversial maneuver.<sup>12,14,15</sup> Proponents recommend sacrificing the SPV to enhance surgical exposure, prevent inadvertent vein avulsion and subsequent hemorrhage, attenuate overzealous retraction, and release the impinged nerve when the conflicting vessel appears to be the SPV itself.<sup>1,2,7–9,13,16–20</sup> On the other hand, opponents indicate that complications can arise after vein sacrifice, and surgeons should try to preserve the SPV as much as possible.14,15,21-28 Several case reports have attributed perioperative complications to SPV sacrifice, including peduncular hallucinosis,<sup>29-31</sup> transient global brainstem dysfunction,<sup>32</sup> contralateral hearing loss,33 delayed contralateral TN,34 cerebellar ataxia due to infarction,35 and fatal hemorrhagic infraction.<sup>36–38</sup> Conversely, there are reports of uneventful SPV ligation<sup>20</sup> and peduncular hallucinosis due to cerebellar retraction.<sup>39</sup> These controversies keep the dilemma ongoing.

To date, high-level evidence comparing the odds of complications after SPV sacrifice versus preservation is lacking.<sup>11,40</sup> This systematic review and meta-analysis seeks to bridge this gap. We hypothesized that the risks of complications were not significantly different between MVD with and without SPV sacrifice.

## Methods

#### Study Design

This systematic review and meta-analysis was conducted according to the guidelines set forth by PRISMA.<sup>41</sup> The study's question per the patient, intervention, comparator, and outcome (PICO) format was as follows: patients were individuals who had TN, glossopharyngeal neuralgia, or hemifacial spasm and underwent MVD; intervention was SPV sacrifice, either inadvertently or intentionally; comparator was SPV preservation; and outcomes were vascular-related complications, neurological deficits, CSF leak, and neuralgia relief.

#### Outcomes

The primary outcome was vascular-related complications, including sinus thrombosis, edema, or ischemia involving the cerebellum or brainstem; secondary outcomes were postoperative new neurological deficits (i.e., postoperative cranial nerve deficit), cerebrospinal fluid (CSF) leak (with or without meningitis), and neuralgia relief.

#### Eligibility Criteria

Studies that met the following criteria were considered eligible for inclusion: 1) comparative studies involving both the intervention and comparator; 2) studies with at least 4 patients in each group; and 3) studies with clearly reported outcomes. Case reports, noncomparative articles, review papers, and articles with unclear outcome reports were excluded. We considered only full-text English articles.

#### Search Strategy

We searched Medline and PubMed databases from inception to October 20, 2021. The following Medical Subject Heading (MeSH) terms and potential keywords were used in various combinations: 1) "Trigeminal Neuralgias" or "Tic Convulsive" or "Trigeminal Neuralgia" or "Tic Doloureux" or "Fothergill Disease" or "Trifacial Neuralgia" or "Trifacial Neuralgias" or "Tic Douloureux" or "Epileptiform Neuralgia" or "Epileptiform Neuralgias" or "Trigeminus Neuralgia" or "Hemifacial Spasms" or "Hemifacial Spasm" or "Unilateral Facial Spasm" or "Unilateral Facial Spasm" or "Hemifacial Myokymia" or "Facial Spasm" or "Glossopharyngeal Neuralgia" or "Glossopharyngeal Neuralgias"; 2) "Decompression Surgery" or "Microvascular Decompression Surgery" or "Microvascular Decompression Surgeries" or "Microvascular Decompression" or "Microvascular Decompressions" or "MVD" or "Microvascular Surgery" or "Microvascular Surgeries"; and 3) "Superior Petrosal Vein" or "Petrosal Vein" or "Dandy's Vein" or "Vein of Dandy" or "Superior Petrosal Sinus" or "Petrosal Sinus" or "Superior Petrosal Complex" or "Superior Petrosal Venous System" or "SPV" or "SPVS"

One author (S.A.S.) performed the search and screened the records on the basis of title and abstract. Irrelevant records were excluded, and the remaining full-text articles were reviewed for eligibility. We supplemented our search by manually screening the text and references of the potentially eligible studies.

#### **Data Extraction**

Two authors (S.A.S. and A.S.) separately extracted the data into two Microsoft Excel sheets, and then the files were cross-checked and verified against the source materials. The corresponding author (J.H.) adjudicated any unresolved discordance. The following data were extracted: first author's name, publication year, country of origin, study design, sample size, age and sex characteristics, outcomes of interest, and follow-up duration.



FIG. 2. PRISMA flow diagram for the study search and inclusion. Data added to the PRISMA template (from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009;6[7]:e1000097) under the terms of the Creative Commons Attribution License.

#### **Risk of Bias Assessment**

The Risk of Bias in Nonrandomized Studies of Intervention (ROBINS-I) tool<sup>42</sup> was used to assess the bias of the included studies.

#### **Statistical Analysis**

The baseline demographic and clinical characteristics of the included studies were summarized with descriptive statistics. Pooled proportions of outcomes (i.e., number of events divided by number of patients) with associated 95% CIs were calculated with the logit transformation method and the DerSimonian and Laird random-effects model by using RStudio version 4.1.2. The ORs for the categorical outcomes with associated 95% CIs were calculated with the Mantel-Haenszel method by using Review Manager (RevMan) version 5.4.1 (The Cochrane Collaboration). With consideration of the clinical diversities and methodological differences between studies, the random-effects model was applied. Heterogeneities between studies were detected using the I<sup>2</sup> test statistic, which attributes proportions of total variation to differences between studies rather than sampling error.<sup>43</sup> All statistical tests were 2-sided, and p < 0.05 was considered statistically significant.

## Results

#### **Study Selection**

Our search strategy resulted in 2069 records, from which 26 duplicate records and 259 non–English language records were removed. We screened the remaining 1784 records on the basis of the titles and abstracts and excluded 1750 studies on irrelevant topics. We reviewed the full text of the remaining 34 articles to assess for eligibility, of which 28 articles were excluded due to the following exclusion criteria: case reports (n = 13), noncomparative studies (n = 5), unclear outcome reports (n = 5), review articles (n = 3), and fewer than 4 patients in the study groups (n = 2). Therefore, we included 6 studies in this systematic review (Fig. 2).<sup>12,17–19,27,44</sup>

#### **Characteristics of the Included Studies**

The included studies were published between 2015 and 2021 and were conducted in the United States (n = 3), United Kingdom (n = 1), France (n = 1), and Japan (n = 1). All included studies were retrospective observational studies, including 1143 microvascular decompression cases, of which 618 underwent SPV sacrifice. The mean age ranged from 32 to 54 years, and 367 (32.4%) patients were male. The SPV was resected to increase surgical exposure, relieve nerve compression, and prevent impeding SPV bleeding. In the population of this systematic review, the pooled proportion (95% CI) values were 3.82 (0.87–15.17) for vascular-related complications, 3.64 (1.0–12.42) for new neurological deficits, 2.85 (1.21–6.58) for CSF leak with and without meningitis, and 88.90 (84.90–91.94) for neuralgia improvement (Table 1).

#### **Risk of Bias Assessment**

The included studies were retrospective nonrandomized studies and were at moderate risk of selection bias and classification bias (Fig. 3).

#### Meta-Analysis of the Outcomes

#### Primary Outcome

*Vascular-Related Complications*. Sixteen events occurred in the SPV-sacrificed cohort versus 8 events in the SPV-preserved group, and the meta-analysis concluded that the odds of vascular-related complications were not significantly different between the sacrificed and preserved cohorts (2.5% vs 1.5%, OR [95% CI] 1.01 [0.33–3.09], p = 0.99,  $I^2 = 0$ ) (Fig. 4).

#### Secondary Outcomes

*New Neurological Deficits.* Eight new deficits occurred in the SPV-sacrificed group versus 15 new deficits in the SPV-preserved group, and the meta-analysis concluded that the risks of new deficit were not significantly different between groups (1.2% vs 2.8%, OR [95% CI] 0.55 [0.18– 1.66], p = 0.29,  $I^2 = 0$ ) (Fig. 5).

*CSF Leak With or Without Meningitis.* Thirteen events in the SPV-sacrificed group relative to 10 events in the SPV-preserved group occurred, and meta-analysis revealed that the risk of CSF leak was not significant between the 2 groups (3.1% vs 2.1%, OR [95% CI] 1.16 [0.46–2.94], p = 0.75,  $I^2 = 0$ ) (Fig. 5).

*Neuralgia Relief.* In total, 273 of 315 SPV-sacrificed patients and 370 of 425 SPV-preserved patients reported neuralgia relief at the follow-up visits. The meta-analysis showed that the 2 groups were not significantly different (86.6% vs 87%, OR [95% CI] 0.96 [0.62–1.49], p = 0.84,  $I^2 = 0$ ) (Fig. 6).

## Discussion

MVD via a retrosigmoid approach is the mainstay treatment for refractory TN, hemifacial spasm, and other cranial nerve rhizopathies. Vascular confliction is the underlying pathology of these types of neuralgia, with the arteries as the most frequent offenders.<sup>1,8,12,13</sup> After bone

removal, "turning the corner" (i.e., exposing the cerebellopontine angle) and engaging with "the vein of Dandy's" (i.e., the SPV) is the most critical step of the retrosigmoid approach and must be executed masterfully.<sup>17,13</sup>

The veins of the posterior fossa are classified into 3 major groups: the galenic group draining into the vein of Galen; the tentorial group emptying into the tentorial sinuses; and the petrosal group draining into the petrosal sinuses.<sup>45–47</sup> The SPV is the upper division of the petrosal group and drains the anterior aspect of the brainstem and cerebellum.<sup>8,45</sup> The main affluents of the SPV are the transverse pontine and pontotrigeminal veins, as well as the veins of the cerebellopontine fissure and the middle cerebellar peduncle. These tributaries merge and form the SPV, usually along the adjacent anterolateral margin of the cerebellum. Then, the SPV courses anterolaterally to join the SPS at a variable point along the petrosal ridge.<sup>11,45–47</sup> The SPV is a prominent landmark during the retrosigmoid approach to the posterior fossa, and the operational field of view is determined on the basis of the drainage patterns of the SPV to the SPS.<sup>8,11</sup> In type I (19% of patients), the SPV drains into the SPS above or lateral to the IAM at a point superolateral to the medial limit of the facial nerve at its point of entry into IAM; in type II (72%), the SPV drains into the SPS between IAM and Meckel's cave at a point lateral to the trigeminal nerve; and in type III (9%), the SPV joins the SPS superior or medial to Meckel's cave at a point medial to the lateral limit of the trigeminal nerve.<sup>11</sup> Therefore, in most patients, the SPV crosses laterally to Meckel's cave and obscures the rectosigmoid corridor, and the surgeon must decide whether to sacrifice or retract the vein; however, this decision is controversial.<sup>1,2,7,8,11,13,40</sup>

To date, sacrificing or preserving Dandy's vein has remained a neurosurgical dilemma, and high-level evidence of the risks of sacrifice versus preservation is lacking.<sup>11,40</sup> To the best of our knowledge, this is the first systematic review and meta-analysis to compare the outcomes of MVD surgery performed with and without SPV sacrifice.

This meta-analysis showed that postoperative morbidities occurred at a relatively low rate. In the cohort of 1143 cranial rhizopathy patients who underwent MVD, the pooled proportions of events per 100 patients were 3.8 for vascular-related complications, 3.6 for new neurological deficits, and 2.8 for CSF leak. Furthermore, there were no fatal complications. The meta-analysis showed that the 2 groups were comparable in terms of postoperative morbidities and treatment success.

#### Morbidity

This study showed that pooled vascular-related complications occurred at rates of 4.7 and 4.1 per 100 patients in the SPV-sacrificed and SPV-preserved cohorts, respectively. These results are consistent with the previously reported rate of complications of 6.2% after SPV sacrifice.<sup>40</sup> Furthermore, the meta-analysis concluded that the risks of vascular-related complications were not statistically different between patients with sacrificed and preserved SPV. These findings indicate that 1) vascular-related complications are infrequent; 2) the petrosal venous complex has sufficient collaterals and therefore most individuals tolerate SPV sacrifice well; and 3) other factors such as venous

J Neurosurg Volume 138 • February 2023 393

TABLE 1. §	Systemat	ic review	and n	neta-ar	alysis of c	outcomes							
		Base	line Ch	aractei	istics				PICO				
										Outc	comes		
Authors & Year*	Country	Study Group	Pts (no.)	Age (yrs)	Male Sex	Pt Description	Intervention	Comparison	Vascular-Related Complication	New Neurological Deficit	CSF Leak w/ or w/o Meningitis	Neuralgia Relief	FU
Dumot &	France	Total	19	32†	9 (47)	TN due	MVD w/ coagulation division	MVD w/	1 (5.2)	3 (15.7)	NR	NR	4.7
Sindou,		SPV-S	12	44†	5 (41)	to SPV	of SPV trunk &/or pontine	preservation of	1 (8.3)	3 (25)	NR	NR	yrs†
2015 <sup>12</sup>		SPV-P	7	39†	4 (57)	conflict	affluent &/or mesencephalic affluent of SPV	SPV by using Teflon pieces	0	0	NR	NR	
Liebelt et	NSA	Total	95	NR	37 (22)	NT	MVD w/ coagulation divi-	MVD w/	8 (8.4)	1 (1)	6 (6.3)	NR	e
al., 2017 <sup>27</sup>		S-V-S	83	56‡	32 (38)		sion of SPV to enhance	preservation of	7 (8.4)	1 (1.2)	6 (7.2)	NR	mos
		SPV-P	12	199	5 (41)		surgical exposure	SPV	1 (8.3)	0	0	NR	
Pathman-	NK	Total	224	57‡	83 (37)	N	MVD w/ SPV sacrifice	MVD w/ SPV	7 (3.1)	0	NR	208 (92.8)	e
aban et		SPV-S	184	NR	NR			preservation	6 (3.2)	0	NR	NR	mos
al., 2017 <sup>17</sup>		SPV-P	40	R	NR			ı	1 (2.5)	0	NR	NR	
Blue et al.,	NSA	Total	201	61‡	51 (26)	TN, HFS,	MVD w/ total (i.e., no re-	MVD w/ SPV	0	4 (2)	2 (1)	145/166 (87.3)	1 mo
202019		SPV-S	118	R	NR	& GPN	maining of SPV branches)	preservation	0	2 (1.7)	1 (0.8)	81/95 (85.2)	
		SPV-P	83	NR	NR		or partial (i.e., remaining of at least 1 SPV branch) sac- rificing of SPV to enhance		0	2 (2.4)	1 (1.2)	64/71 (90.1)	
							surgical exposure or when impeding SPV-related bleeding was anticipated						
Xia et al.,	USA	Total	592	54†	187 (31)	TN & HFS	MVD w/ sacrifice of SPV	MVD w/ SPV	2 (0.3)	11 (1.8)	15 (2.5)	487/562 (86.6)	1 mo
2020 <sup>18</sup>		S-V-S	217	55†	74 (34)		or affluent(s) of SPV to	preservation	0	1 (0.4)	6 (2.7)	188/216 (87)	
		SPV-P	375	53†	113 (30)		enhance surgical exposure		2 (0.5)	10 (2.6)	9 (2.4)	299/346 (86.4)	
Kasuya	Japan	Total	12	NR	NR	TN due	MVD w/ coagulation &	MVD w/ SPV	6 (50)	4 (33.3)	NR	11 (91.6)	4.5
et al.,		SPV-S	4	NR	NR	to SPV	sacrifice of SPV	preservation by	2 (50)	1 (25)	NR	4 (100)	yrs†
S <sup>4+</sup> 1202		SPV-P	∞	R	NR	conflict		using transpo-	4 (50)	3 (37.5)	NR	7 (87.5)	
		SPV-P	8	NR	NR			sillori & lixaliori technique	4 (50)	3 (37.5)	NR	7 (87.5)	
Overall no.		Total	1143						3.82 (0.87–15.17)	3.64 (1.0–12.42)	2.85 (1.21–6.58)	88.90 (84.90–91.94)	
& pooled		S-V-S	618						4.73 (1.44–14.43)	2.76 (0.54–12.99)	3.32 (1.22–8.77)	86.52 (82.29–89.87)	
propor- tions (95% CI)¶		SPV-P	525						4.17 (0.61–23.54)	4.99 (1.52–15.13)	2.30 (1.26–4.16)	86.99 (83.43–89.87)	
FU = follow- Values are s * All included	up; GPN = hown as ni I studies w	glossopha umber (%) ere retrosp	iryngeal unless i ective a	neuralç ndicate and obse	jia; HFS = h∉ d otherwise. ervational.	emifacial spası	n; NR = not reported; Pt = patien	t; SPV-P = SPV-pre	sserve; SPV-S = SP\	/-sacrifice; UK = Unite	ed Kingdom.		
† Mean valu ‡ Median val	es are sho ues are sh	NN. OWN.											
§ Reported {	58 patients 1 proportio	(39 femals 1s show th	e estima	9 males ated nur	; mean age nber of even	59.4 years) wil tts per 100 pat	:h TN due to isolated venous coni ients.	flict; of these, 12 SF	<sup>o</sup> V-related neuralgia	cases were enrolled i	n the systematic revie	w and meta-analysis.	

#### Sattari et al.

394 J Neurosurg Volume 138 • February 2023

Study and Year	Risk	of b	ias in	non-	rando	mized	studi	es of
	inter	rventio	ons (R	OBIN	S-I) D	omain	S*	
	1	2	3	4	5	6	7	8
Dumot & Sindou, 201512	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$
Leibelt et al., 2017 27	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$
Pathmanaban et al., 2017 <sup>17</sup>	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$
Blue et al., 2020 19	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$
Xia et al., 2020 18	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$
Kasuya et al., 2021 44	$\bigcirc$	$\bigcirc$	$\bigcirc$					$\bigcirc$

Symbols: **\*** ROBINS-I domains: 1, baseline confounding; 2, participants' enrollment; 3, interventions' classification; 4, deviation from intended interventions; 5, incomplete outcome data; 6, measurement of the outcomes; 7, selective reporting; 8, overall risk of bias. Gray=Moderate risk, **Black= Low risk**.

FIG. 3. Risk of bias assessment.

anomalies and/or improper execution of surgery are potential offenders in patients with complications.

Numerous case reports have attributed perioperative complications to SPV resection.<sup>29-38</sup> However, the territory and resection of SPV cannot explain all these events. Here, we have provided details of some of these events. Peduncular hallucinosis is a dream-like visual hallucination that is presumably due to lesions affecting paramedian reticular formations and the pontine-geniculate-occipital pathway.<sup>48–50</sup> To date, of the 4 studies that reported transient peduncular hallucinosis after MVD surgery,<sup>29-39</sup> 3 postulated that SPV resection was the underlying cause.<sup>29-31</sup> However, in the study by Tsukamoto et al., SPV was avulsed inadvertently, leading to posterior fossa hemorrhage. It seems that subsequent perforating artery vasospasm was the culprit etiology that led to hallucinosis.<sup>29</sup> Interestingly, Miyazawa et al. preserved the SPV, and cerebellar retraction was the underlying cause of peduncular hallucinosis.39

Strauss et al. sacrificed the pontotrigeminal affluent of the SPV during MVD of TN. Three days later, the patient sustained contralateral hearing loss due to inferior colliculus congestion attributed to the SPV territory.<sup>33</sup> Although the lateral mesencephalic vein of the inferior colliculus has an anastomosis with the pontotrigeminal vein, it has also other collaterals and predominantly drains into the basal vein. In addition, the collicular plate has a rich venous plexus that mainly drains into galenic vein groups.<sup>47</sup> Such a case is rare (0.08% of patients)<sup>2</sup> and occurs in the setting of venous aberration and/or iatrogenic vessel injury. The most dreadful complication attributed to SPV resection is fatal hemorrhagic infarction.<sup>36–38</sup> However, Singh et al. reported extensive infarction after SPV avulsion in a case with an underlying anomaly of the right transverse sinus, right sigmoid sinus, and internal jugular vein.<sup>36</sup> Of note, the SPV territory cannot justify the extension of infarction to the supratentorial region, thalamus, and temporal lobe, as reported by Anichini et al.<sup>37</sup> In later studies, most vascular-related complications were edema and sinus thrombosis.<sup>17–19,27</sup> and no vascular-related complications occurred in the SPV-sacrificed groups of 2 cohort studies.<sup>18,19</sup>

It is worth noting that the complications in the SPVsacrificed cohort included those associated with inadvertent SPV avulsion. SPV avulsion usually occurs owing to overzealous cerebellar retraction leading to torrential hemorrhage. Controlling such hemorrhage is challenging because the venous ends retract within the arachnoid sleeve or dural folds, and repeated attempts to stop bleeding further damage the tissue. However, the chance of complications is lower if the surgeons resect the SPV in a controlled manner.<sup>9,13</sup>

Cranial nerve injuries constituted the new postoperative neurological deficits in the reviewed studies.<sup>12,17–19,27,44</sup> Trying to preserve the SPV as much as possible may sound appealing, but doing so is cumbersome and tricky. Although the meta-analysis showed comparable odds of new postoperative neurological deficit, patients with sacrificed SPV had fewer new neurological deficits. When the SPV encroaches into the surgical field of view, it must be either sacrificed or retracted. Apart from retraction-related injuries, continuing the operation despite an inadequate view increases the risk of iatrogenic injury to adjacent structures such as cranial nerves.

Despite advancements in MVD techniques, CSF leak is a concerning postoperative morbidity with a reported rate of 1.5% to 14.5%.<sup>51,52</sup> The pooled proportion of CSF leaks was 2.85 per 100 patients. Several factors may predispose patients to CSF leak, of which dural and bony closure are the most important, and this meta-analysis showed that the odds of CSF leak were similar with and without SPV sacrifice.<sup>52</sup>

#### Neuralgia Relief

It is unclear whether SPV preservation or sacrifice al-



FIG. 4. Forest plots showing the ORs for vascular-related complications after MVD with sacrifice versus preservation of the SPV. M-H = Mantel-Haenszel.



FIG. 5. Forest plots showing the ORs for new neurological deficits (A) and CSF leak with and without meningitis (B) after MVD with sacrifice versus preservation of the SPV.

ters treatment outcomes. Some authors hypothesized that SPV preservation may reduce the success rate due to impeded access.<sup>17,18</sup> The meta-analysis showed that 89% of patients achieved neuralgia relief with MVD surgery and further concluded that the likelihood of MVD success is comparable regardless of whether the surgeon sacrifices or preserves the SPV.

#### Limitations

We acknowledge several limitations. First, we included retrospective cohort studies with moderate risk of bias. However, conducting a prospective randomized trial to compare sacrifice versus preservation of the SPV would be challenging due to ethical underpinnings<sup>53</sup> and the low proportion of the events would require a relatively large sample size. In this systematic review of 1143 patients, the primary outcome event rate was 0.02 (16/618) in the SPVsacrificed group and 0.01 (8/525) in the SPV-preserved group. With consideration of the statistical characteristics of this study ( $\rho_1 = 0.02$ ,  $\rho_2 = 0.01$ ,  $\alpha = 0.05$ , and  $\beta = 0.8$ ), a randomized controlled trial in this setting requires at least 456 randomized patients in each arm (i.e., 912 patients in total). Therefore, the current meta-analysis reached the optimal information size and has sufficient statistical power. Second, these studies did not report the outcomes of MVD stratified on the basis of underlying cranial nerve rhizopathies and intentional versus inadvertent venous sacrifice. Therefore, we were unable to perform a subgroup meta-analysis. Third, we only searched the Medline and PubMed databases and included studies with English text. Fourth, other postoperative outcomes, such as hospital stay, reoperation, and neuralgia recurrence, were not evaluated.

## Conclusions

The risks of operation-related morbidities and treatment success rates were not statistically different between patients with and without sacrificed SPV. Most individuals have well-established collaterals and properly tolerate SPV resection. Vascular-related complications are rare and limited to edema and venous thrombosis. Devastating complications can arise due to underlying venous anomalies or improper execution of surgery. SPV sacrifice is as safe as its preservation. We recommend



FIG. 6. Forest plots showing the ORs for neuralgia relief after MVD with sacrifice versus preservation of the SPV.

SPV sacrifice when gentle retraction fails to increase the surgical view and if the surgeon encounters SPV-related neurovascular conflict and/or anticipates impeding SPV-related bleeding.

## References

- Jannetta PJ, McLaughlin MR, Casey KF. Technique of microvascular decompression. *Neurosurg Focus*. 2005;18(5):E5.
- Barker FG II, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-1083.
- Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. *J Neurosurg*. 2002;96(3):532-543.
- Hitotsumatsu T, Matsushima T, Inoue T. Microvascular decompression for treatment of trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: three surgical approach variations: technical note. *Neurosurgery*. 2003;53(6): 1436-1443.
- Sarsam Z, Garcia-Fiñana M, Nurmikko TJ, Varma TRK, Eldridge P. The long-term outcome of microvascular decompression for trigeminal neuralgia. *Br J Neurosurg*. 2010;24(1): 18-25.
- 6. Rosenstengel C, Matthes M, Baldauf J, Fleck S, Schroeder H. Hemifacial spasm: conservative and surgical treatment options. *Dtsch Arztebl Int*. 2012;109(41):667-673.
- 7. Broggi G, Broggi M, Ferroli P, Franzini A. Surgical technique for trigeminal microvascular decompression. *Acta Neurochir (Wien).* 2012;154(6):1089-1095.
- Dandy WE. An operation for the cure of tic douloureux: partial section of the sensory root at the pons. *Arch Surg.* 1929; 18(2):687-734.
- 9. Choudhari KA. Superior petrosal vein in trigeminal neuralgia. *Br J Neurosurg*. 2007;21(3):288-292.
- 10. Perese DM. Superficial veins of the brain from a surgical point of view. *J Neurosurg*. 1960;17:402-412.
- Tanriover N, Abe H, Rhoton ALJ Jr, Kawashima M, Sanus GZ, Akar Z. Microsurgical anatomy of the superior petrosal venous complex: new classifications and implications for subtemporal transtentorial and retrosigmoid suprameatal approaches. *J Neurosurg*. 2007;106(6):1041-1050.
- Dumot C, Sindou M. Trigeminal neuralgia due to neurovascular conflicts from venous origin: an anatomical-surgical study (consecutive series of 124 operated cases). *Acta Neurochir (Wien)*. 2015;157(3):455-466.
- McLaughlin MR, Jannetta PJ, Clyde BL, Subach BR, Comey CH, Resnick DK. Microvascular decompression of cranial nerves: lessons learned after 4400 operations. *J Neurosurg*. 1999;90(1):1-8.
- Matsushima T, Huynh-Le P, Miyazono M. Trigeminal neuralgia caused by venous compression. *Neurosurgery*. 2004; 55(2):334-339.
- Matsushima K, Matsushima T, Kuga Y, et al. Classification of the superior petrosal veins and sinus based on drainage pattern. *Neurosurgery*. 2014;10(suppl 2):357-367.
- Li GW, Zhang WC, Yang M, Ma QF, Zhong WX. Clinical characteristics and surgical techniques of trigeminal neuralgia caused simply by venous compression. *J Craniofac Surg.* 2014;25(2):481-484.
- Pathmanaban ON, O'Brien F, Al-Tamimi YZ, Hammerbeck-Ward CL, Rutherford SA, King AT. Safety of superior petrosal vein sacrifice during microvascular decompression of the trigeminal nerve. *World Neurosurg.* 2017;103:84-87.
- Xia Y, Kim TY, Mashouf LA, et al. Absence of ischemic injury after sacrificing the superior petrosal vein during microvascular decompression. *Oper Neurosurg (Hagerstown)*. 2020;18(3):316-320.

- Blue R, Li C, Spadola M, Saylany A, McShane B, Lee JYK. Complication rates during endoscopic microvascular decompression surgery are low with or without petrosal vein sacrifice. *World Neurosurg*. 2020;138:e420-e425.
- Gajski D, Dennis AR, Arnautović KI. Microsurgical decompression of trigeminal neuralgia caused by simultaneous double arterial (SCA and AICA) and petrosal vein complex compression. *J Neurol Surg B Skull Base*. 2018;79(5)(suppl 5):S428-S430.
- 21. Kimura T, Sako K, Tohyama Y, Yonemasu Y. Trigeminal neuralgia caused by compression from petrosal vein transfixing the nerve. *Acta Neurochir (Wien)*. 1999;141(4):437-438.
- Zhong J, Li ST, Xu SQ, Wan L, Wang X. Management of petrosal veins during microvascular decompression for trigeminal neuralgia. *Neurol Res.* 2008;30(7):697-700.
  Zhong J, Zhu J, Sun H, et al. Microvascular decompression
- Zhong J, Zhu J, Sun H, et al. Microvascular decompression surgery: surgical principles and technical nuances based on 4000 cases. *Neurol Res.* 2014;36(10):882-893.
- 24. Zhao Y, Zhang X, Yao J, Li H, Jiang Y. Microvascular decompression for trigeminal neuralgia due to venous compression alone. *J Craniofac Surg.* 2018;29(1):178-181.
- Zhong J, Li ST, Zhu J, et al. A clinical analysis on microvascular decompression surgery in a series of 3000 cases. *Clin Neurol Neurosurg*. 2012;114(7):846-851.
- Zhao X, Hao S, Wang M, Han C, Xing D, Wang C. Management of veins during microvascular decompression for idiopathic trigeminal neuralgia. *Br J Neurosurg*. 2018;32(5): 484-488.
- 27. Liebelt BD, Barber SM, Desai VR, et al. Superior petrosal vein sacrifice during microvascular decompression: perioperative complication rates and comparison with venous preservation. *World Neurosurg*. 2017;104:788-794.
- 28. Guerrero J, Huang M, Britz G. Double crush syndrome as a cause of hemifacial spasm. *Cureus*. 2021;13(1):e12448.
- Tsukamoto H, Matsushima T, Fujiwara S, Fukui M. Peduncular hallucinosis following microvascular decompression for trigeminal neuralgia: case report. *Surg Neurol*. 1993;40(1): 31-34.
- Chen HJ, Lui CC. Peduncular hallucinosis following microvascular decompression for trigeminal neuralgia: report of a case. J Formos Med Assoc. 1995;94(8):503-505.
- Koerbel A, Wolf SA, Kiss A. Peduncular hallucinosis after sacrifice of veins of the petrosal venous complex for trigeminal neuralgia. *Acta Neurochir (Wien)*. 2007;149(8):831-833.
- Vulcan AW, Ferch RD, Teddy PJ. Transient global brainstem dysfunction after microvascular decompression of the trigeminal nerve. *Br J Neurosurg*. 2004;18(3):275-277.
- Strauss C, Naraghi R, Bischoff B, Huk WJ, Romstöck J. Contralateral hearing loss as an effect of venous congestion at the ipsilateral inferior colliculus after microvascular decompression: report of a case. *J Neurol Neurosurg Psychiatry*. 2000; 69(5):679-682.
- Eibach S, Steinfort B, Di Ieva A. Delayed contralateral trigeminal neuralgia after microvascular decompression and postoperative changes in venous outflow. *World Neurosurg*. 2020;140:107-108.
- Masuoka J, Matsushima T, Hikita T, Inoue E. Cerebellar swelling after sacrifice of the superior petrosal vein during microvascular decompression for trigeminal neuralgia. *J Clin Neurosci.* 2009;16(10):1342-1344.
- Singh D, Jagetia A, Sinha S. Brain stem infarction: a complication of microvascular decompression for trigeminal neuralgia. *Neurol India*. 2006;54(3):325-326.
- Anichini G, Iqbal M, Rafiq NM, Ironside JW, Kamel M. Sacrificing the superior petrosal vein during microvascular decompression. Is it safe? Learning the hard way. Case report and review of literature. *Surg Neurol Int*. 2016;7(14)(suppl 14):S415-S420.
- 38. Ryu H, Yamamoto S, Sugiyama K, Yokota N, Tanaka T. Neu-

J Neurosurg Volume 138 • February 2023 397

#### Sattari et al.

rovascular decompression for trigeminal neuralgia in elderly patients. *Neurol Med Chir (Tokyo)*. 1999;39(3):226-230.

- 39. Miyazawa T, Ito M, Yasumoto Y. Peduncular hallucinosis following microvascular decompression for trigeminal neuralgia without direct brainstem injury: case report. *Acta Neurochir* (*Wien*). 2009;151(3):285-286.
- Narayan V, Savardekar AR, Patra DP, et al. Safety profile of superior petrosal vein (the vein of Dandy) sacrifice in neurosurgical procedures: a systematic review. *Neurosurg Focus*. 2018;45(1):E3.
- 41. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *J Clin Epidemiol*. 2021;134:178-189.
- 42. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.
- von Hippel PT. The heterogeneity statistic I<sup>2</sup> can be biased in small meta-analyses. *BMC Med Res Methodol*. 2015;15:35.
- Kasuya H, Tani S, Kubota Y, et al. Characteristics and management of the offending veins in microvascular decompression surgery for trigeminal neuralgia. *Neurosurg Rev.* 2021; 44(4):2337-2347.
- Huang YP, Wolf BS, Antin SP, Okudera T. The veins of the posterior fossa—anterior or petrosal draining group. Am J Roentgenol Radium Ther Nucl Med. 1968;104(1):36-56.
- Matsushima T, Rhoton ALJ Jr, de Oliveira E, Peace D. Microsurgical anatomy of the veins of the posterior fossa. J Neurosurg. 1983;59(1):63-105.
- 47. Rhoton ALJ Jr. The posterior fossa veins. *Neurosurgery*. 2000;47(3)(suppl):S69-S92.
- Dunn DW, Weisberg LA, Nadell J. Peduncular hallucinations caused by brainstem compression. *Neurology*. 1983;33(10): 1360-1361.
- Kölmel HW. Peduncular hallucinations. J Neurol. 1991; 238(8):457-459.

- 50. Roser F, Ritz R, Koerbel A, Loewenheim H, Tatagiba MS. Peduncular hallucinosis: insights from a neurosurgical point of view. *Neurosurgery*. 2005;57(5):E1068.
- Eseonu CI, Goodwin CR, Zhou X, et al. Reduced CSF leak in complete calvarial reconstructions of microvascular decompression craniectomies using calcium phosphate cement. J Neurosurg. 2015;123(6):1476-1479.
- Stoker MA, Forbes JA, Hanif R, et al. Decreased Rate of CSF Leakage Associated with Complete Reconstruction of Suboccipital Cranial Defects. *J Neurol Surg B Skull Base*. 2012; 73(4):281-286.
- 53. Colli A, Pagliaro L, Duca P. The ethical problem of randomization. *Intern Emerg Med*. 2014;9(7):799-804.

#### Disclosures

Dr. Bettegowda is a consultant for DePuy-Synthes, Bionaut Labs, and Galectin Therapeutics; and is the founder of OrisDx. Dr. Huang owns stock in Longeviti.

#### **Author Contributions**

Conception and design: Huang, Sattari, Xu, Hung, Bettegowda. Acquisition of data: Huang, Sattari, Shahbandi, Xu, Hung, Bettegowda. Analysis and interpretation of data: all authors. Drafting the article: Huang, Sattari, Shahbandi. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Huang. Statistical analysis: Sattari, Feghali. Study supervision: Huang, Xu, Hung, Bettegowda.

#### Correspondence

Judy Huang: Johns Hopkins University School of Medicine, Baltimore, MD. jhuang24@jhmi.edu.